Invitrogen and Natural Selection to Make new microRNA Sequences
News Oct 05, 2007
Invitrogen Corporation has announced that it has entered into a licensing agreement with Natural Selection, Inc. to make new microRNA sequences available to researchers. This agreement enables Invitrogen to provide the most comprehensive human and mouse microRNA arrays on the market.
The microRNA sequences have been verified experimentally using deep sequencing, array profiling, and qRT-PCR methods. Invitrogen claims to be the first company to commercialize microRNA content discovered using these new deep sequencing technologies.
The agreement will lead to a significant increase in human and mouse microRNA content on the market and available to researchers. The microRNA sequences will be submitted to the on-line database of The Sanger Institute, a leading biomedical research charity. Its on-line database, recently updated to 10.0 version, is the world repository for microRNA sequences.
“For the first time, scientists will be able to investigate the role of many novel and previously unknown microRNAs using Invitrogen’s microRNA arrays with Natural Selection content,” said Amy Butler, Invitrogen Vice President of Gene Expression Profiling. “By combining these new sequences with the latest Sanger 10.0 content, we are greatly expanding the potential for discovery of novel microRNA biomarkers for disease and development.”
Also as part of the agreement, Invitrogen will make available a larger set of computationally-predicted microRNA sequences over the next few years for human and mouse resulting from a proprietary design algorithm developed by Natural Selection, Inc. under funding from the National Science Foundation.
“These new tools will significantly enhance the research community’s understanding of the role of small RNAs in biological processes,” said Dr. Gary Fogel, Vice President of Natural Selection. “This advance is particularly important in the areas of cancer and stem cell research, where microRNAs have been found to play a critical role. We are very pleased to team with Invitrogen to make these sequences available to the research community.”